T1	Participants 183 195	464 patients
T2	Participants 86 142	intermediate-grade and high-grade non-Hodgkin's lymphoma
T3	Participants 377 424	patients with aggressive non-Hodgkin's lymphoma
T4	Participants 760 811	intermediate- and high-grade non-Hodgkin's lymphoma
T5	Participants 1761 1769	patients
